cancer treatment

AstraZeneca has invested $2bn in US biotech firm Summit Therapeutics as part of a major cancer research collaboration. The FTSE 100 drugmaker agreed to buy 109,000 shares in the Nasdaq-listed company at $18.36 per share, funding a tie-up aimed at developing new cancer treatments.

New reporting highlights that people who survived cancer in childhood face a significantly elevated risk of serious mental health difficulties in adulthood, including depression, anxiety and other psychiatric conditions. The findings point to long-term psychological effects of early cancer diagnosis and treatment, and renew calls for survivors to receive sustained mental health monitoring and support, not just physical follow-up care, well into their adult lives.

Researchers led by Dr. Jona Kayser at MPZPM report that physical processes in dense cell populations strongly influence the best timing of treatment cycles, with implications for both cancer therapy and antibiotics. Treatment resistance remains one of the central challenges in medicine, and the findings suggest that timing could be adjusted based on how tightly cells pack together rather than on biology alone. The work points to new ways of scheduling therapies to delay or avoid resistance.

Researchers report observing how an aggressive brain cancer physically remodels brain tissue as it grows, offering a live view of tumor progression. The findings shed light on how deadly brain tumors invade and distort surrounding structures, which could inform future treatment approaches. The work is drawing attention for its striking visualization of the disease's effects on the brain.

A new trial reports that stereotactic radiosurgery improves survival for patients with small cell lung cancer that has spread to the brain. The findings challenge the routine use of whole-brain radiation therapy for these patients and are drawing attention among oncologists, with searches about cancer trending in Australia and France.

Coverage is circulating of the second part of a highlights roundup from the World Cancer Congress 2026, summarising key presentations and developments shared at the global oncology gathering. The roundup is aimed at cancer professionals and researchers following the congress remotely, distilling sessions into digestible takeaways. Interest centres on what new research, treatment approaches and policy discussions were featured at this year's event.

Biotech company Vyriad has begun the first-in-human clinical trial of VV169, an in vivo CAR T therapy that engineers immune cells inside the patient's body rather than in a lab. The early-stage trial marks a first step in testing the safety of the experimental cancer treatment in people, an approach watched closely as it could simplify a cell therapy process that is currently complex and costly.

A new report outlines how biological research is changing the way breast cancer is diagnosed and treated. Understanding tumour biology is increasingly guiding treatment choices, moving care away from one-size-fits-all approaches toward therapies matched to the specific characteristics of each patient's cancer. The piece has drawn attention from clinicians and patient advocates following shifts in treatment standards.

New research suggests that analysing the biology of prostate cancer tumours can help doctors identify which patients are most likely to benefit from hormone therapy. The findings could support more personalised treatment decisions, allowing clinicians to target therapy at those most likely to respond rather than applying it universally. The report has drawn attention in medical news coverage.

Mount Sinai has announced a collaborative research agreement to evaluate a novel liquid radioembolic agent for treating brain tumors. The therapy would deliver radiation directly to tumor tissue in liquid form, an approach being explored for cancers that are difficult to treat surgically. Details on the partner institution, trial design and timeline have not yet been released, and clinical results remain pending.

Volunteers and advocates with the American Cancer Society's Cancer Action Network visited Capitol Hill to meet with members of Congress, urging support for cancer research funding and patient-focused legislation. The advocacy day brings grassroots concerns about prevention, treatment access, and federal research investment directly to lawmakers, and is part of the organization's ongoing effort to keep cancer policy on the national legislative agenda.

NPR has published the story of a professor who was diagnosed with lung cancer and underwent cutting-edge treatment, reportedly involving mRNA-based approaches and questions of affordability. The piece follows his shift from expert observer to patient navigating new therapies. It is drawing attention as a personal account of where lung cancer treatment stands and who can access it.

Researchers have highlighted three previously overlooked RNA molecules as potential new markers for colorectal cancer. The findings suggest these molecules could help detect the disease earlier and guide treatment choices, offering a possible addition to existing screening and diagnostic tools. Colorectal cancer remains one of the most common cancers worldwide, so any lead on earlier detection is drawing scientific and media attention.

A New York Times opinion piece asks why clinical trials for cancer drugs take so long, examining delays in the process of testing new treatments on patients. The article prompts discussion about whether trial design, regulatory requirements, or patient recruitment are the main bottlenecks in getting promising cancer therapies to people faster.

A new study has found that infections cause roughly one in eight cancer cases worldwide. The finding points to the significant role viruses and bacteria play in triggering cancers, suggesting prevention through vaccination and treatment of infections could substantially reduce the global cancer burden.

A new study reports that a combination of vitamin C and DMSO produced promising results against skin cancer, with reported elimination of lesions in 56% of cases within 12 weeks and 94% of patients avoiding surgery. Other research suggests DMSO may enhance delivery of anticancer drugs directly into tumors, and early reports involving ivermectin are also circulating.

An essay in Aeon argues that the word 'cancer' should be used far more cautiously, since the term lumps together conditions of wildly different danger and leads to overdiagnosis and overtreatment. The author calls for a better vocabulary to describe what is often called cancer, arguing that language shapes how patients understand risk and choose treatment.

Dr. Ilyas Sahin has drawn attention to a new scientific study on colorectal cancer liver metastasis, one of the most common and difficult sites of colorectal cancer spread. The findings are being shared among oncology watchers interested in how the disease progresses and what new treatment approaches might follow.

Doctors are highlighting theranostics, an emerging approach to treating advanced prostate cancer that pairs diagnostic imaging with targeted therapy in a single process. The method allows physicians to detect cancer cells and deliver radiation treatment directly to them, potentially improving outcomes for patients whose disease no longer responds to standard therapies.

Haga Bioscience and Imagenomix have announced a partnership to develop AI-based spatial biomarker analysis for cancer pathology. The collaboration aims to combine spatial biology techniques with artificial intelligence to improve how biomarkers are measured in tumor tissue, potentially supporting more precise cancer diagnosis and treatment decisions.

Will Reeve, an ABC News correspondent and son of the late Superman actor Christopher Reeve, has announced that he has been diagnosed with testicular cancer and is undergoing chemotherapy treatment. The news is being picked up widely by US media outlets, with viewers and colleagues offering support and praising his decision to share the diagnosis publicly.